EP0701802A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Drug eluting stent
Assignee: Medtronic Inc
•
Filing: 1995-09-15
•
Granted: —
•
Expires: 2015-09-15
Abstract
Abstract A drug eluting intravascular stent comprising: (a) a generally cylindrical stent body; (b) a solid composite of a polymer and a therapeutic substance in an adherent layer on the stent body; and (c) fibrin in an adherent layer on the composite. This may be prepared by the steps of: (a) providing a generally cylindrical stent body; (b) forming on said stent body a layer of a solid composite of polymer and therapeutic substance; and (c) forming over said composite a layer of fibrin. Such stents may be used in combatting restenosis.
Inventors
- 👤 Thomas Q. Dinh
- 👤 Ronald J. Tuch
- 👤 Robert S. Schwartz
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 22:35
CPC Classifications
A; A61; A61F; A61F2/00; A61F2/82; A61L; A61L31/00; A61L31/04; A61L31/041; A61L31/043; A61L31/046; A61L31/047; A61L31/08; A61L31/10; A61L31/12; A61L31/125; A61L31/128; A61L31/14; A61L31/16; A61F2/0077; A61F2240/00; A61F2240/001; A61F2250/00; A61F2250/0058; A61F2250/0067; A61L2300/00; A61L2300/20; A61L2300/252; A61L2300/40; A61L2300/416; A61L2300/60; A61L2300/606; A61L2420/00; A61L2420/08; B; B05; B05C; B05C3/00; B05C3/20; Y; Y10; Y10S; Y10S623/00; Y10S623/92; Y10S623/921
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
41 words
A drug eluting intravascular stent comprising: (a) a generally cylindrical stent body; (b) a solid composite of a polymer and a therapeutic substance in an adherent layer on the stent body; and (c) fibrin in an adherent layer on the composite.
Claim 2
Dependent Claim
15 words
A stent as claimed in claim 1 wherein the said body has a metal surface.
Claim 3
Dependent Claim
15 words
A stent as claimed in claim 1 wherein said stent body has a polymeric surface.
Claim 4
Dependent Claim
21 words
A stent as claimed in any one of claims 1 to 3 wherein said solid composite comprises a plurality of layers.
Claim 5
Dependent Claim
23 words
A stent as claimed in claim 4 wherein the ratio of therapeutic substance to polymer is not the same in all said layers.
Claim 6
Dependent Claim
20 words
A stent according as claimed in any one of claims 1 to 5 wherein said polymer is a bioabsorbable polymer.
Claim 7
Dependent Claim
19 words
A stent as claimed in claim 6 wherein said polymer is selected from fibrin, poly(L-lactic acid), poly(lactide-co-glycolide) and poly(hydroxybutyrate-co-valerate).
Claim 8
Dependent Claim
19 words
A stent as claimed in any one of claims 1 to 5 wherein said polymer is a biostable polymer.
Claim 9
Dependent Claim
27 words
A stent as claimed in claim 8 wherein said polymer is selected from silicones, polyurethanes, polyesters, vinyl homopolymers and copolymers, acrylate homopolymers and copolymers, polyethers and cellulosics.
Claim 10
Dependent Claim
32 words
A stent as claimed in any one of claims 1 to 9 wherein the ratio of therapeutic substance to polymer in said solid composite is in the range of 10:1 to 1:100.
Claim 11
Dependent Claim
42 words
A stent as claimed in any one of claims 1 to 10 wherein said therapeutic substance is selected from glucocorticoids, heparin, hirudin, tocopherol, angiopeptin, aspirin, ACE inhibitors, growth factors, oligonucleotides, antiplatelet agents, anticoagulant agents, antimitotic agents, antioxidants, antimetabolite agents, and anti-inflammatory agents.
Claim 12
Independent Claim
49 words
A method of producing a drug eluting intravascular stent, said method comprising the steps of: (a) providing a generally cylindrical stent body; (b) forming on said stent body a layer of a solid composite of polymer and therapeutic substance; and (c) forming over said composite a layer of fibrin.
Claim 13
Dependent Claim
56 words
A method as claimed in claim 12 wherein said layer of solid composite is formed by: (a) applying to said stent body a solution which comprises a solvent, a polymer dissolved in said solvent and a therapeutic substance dispersed in said solvent; and (b) evaporating said solvent to form a composite of polymer and therapeutic substance;
Claim 14
Dependent Claim
14 words
A method as claimed in claim 13 wherein said solution is applied by spraying.
Claim 15
Independent Claim
25 words
A method as claimed in either of claims 13 and 14 wherein a said solution is applied in a plurality of application and evaporation steps.
Claim 16
Dependent Claim
31 words
A method as claimed in claim 15 wherein the ratio of therapeutic substance to dissolved polymer in said solution is not the same in all of said plurality of application steps.
Claim 17
Dependent Claim
57 words
A method as claimed in claim 12 wherein said layer of solid composite is formed by: (a) applying to said stent body a solution which includes fibrinogen; (b) applying thrombin to the fibrinogen on the stent body to effect polymerization of the fibrinogen; and (c) applying a therapeutic substance to the fibrinogen as the fibrinogen is polymerizing.
Claim 18
Dependent Claim
49 words
A method as claimed in claim 12 wherein said layer of solid composite is formed by: (a) applying to said stent body a solution which includes fibrinogen and a dispersed therapeutic substance; and (b) applying thrombin to the fibrinogen on said stent body to effect polymerization of the fibrinogen.
Claim 19
Independent Claim
31 words
A method as claimed in any one of claims 12 to 18 wherein said layer of fibrin is formed by molding a polymerization mixture of fibrinogen and thrombin onto said composite.
References Cited (Backward Citations)
EP0166263A1
Cited
EP0649637A1
Cited
EP0420541A2
Cited
WO1991017789A1
Cited
EP0566245A1
Cited
EP0604022A1
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.